EnsoData is a healthcare technology company that builds AI-powered software solutions to improve the diagnosis, management, and treatment of sleep disorders. Its flagship product, EnsoSleep, is an FDA-cleared, cloud-based platform that uses artificial intelligence and machine learning to analyze sleep study data from polysomnography (PSG) and home sleep apnea tests (HSATs). EnsoData serves sleep clinics, healthcare providers, and health systems, enabling faster, more accurate, and cost-effective diagnoses and therapy management. The company has demonstrated strong growth momentum by expanding its product capabilities, including recent innovations in photoplethysmography (PPG)-based sleep analysis and remote physiological monitoring (RPM), and by supporting over 1 million patient diagnoses across 500+ clinics and 100+ provider organizations[1][2][3][5].
Founded in 2015 and headquartered in Madison, Wisconsin, EnsoData was created by a team combining clinical sleep expertise and AI technology. The idea emerged from the need to address inefficiencies and inaccuracies in traditional sleep disorder diagnosis workflows. Early traction came from the development and FDA clearance of EnsoSleep, which automated complex waveform analysis and scoring, significantly reducing clinician workload and turnaround times. The company’s evolution has been marked by continuous product innovation, including expanding into pediatric sleep apnea diagnosis and integrating home-based testing technologies, reflecting a commitment to improving accessibility and quality of sleep care[1][6][7].
EnsoData rides the growing trend of applying artificial intelligence and cloud computing to healthcare diagnostics, specifically in sleep medicine—a $100 billion market with significant unmet needs. The timing is critical as sleep disorders are increasingly recognized for their impact on overall health, and healthcare systems seek scalable, cost-effective diagnostic tools. Market forces such as rising demand for home-based testing, telehealth expansion, and regulatory support for AI-driven medical devices favor EnsoData’s growth. By streamlining the sleep care pathway from diagnosis to therapy, EnsoData influences the broader ecosystem by enabling providers to improve patient outcomes, reduce costs, and expand access to care[1][2][5].
Looking ahead, EnsoData is positioned to deepen its impact by expanding its AI capabilities, integrating more remote monitoring features, and potentially entering new diagnostic areas beyond sleep medicine. Trends such as increased adoption of wearable health devices, personalized medicine, and value-based care models will shape its journey. The company’s influence is likely to grow as it continues to lower barriers to sleep disorder diagnosis and treatment, helping healthcare providers deliver more proactive and patient-centered care. EnsoData’s blend of clinical expertise and cutting-edge AI technology sets a strong foundation for sustained innovation and leadership in digital health diagnostics[3][5].
EnsoData has raised $51.0M in total across 4 funding rounds.
EnsoData's investors include Ulu Ventures, Zetta Venture Partners, Baird Capital, Colle Capital, gener8tor, Blockchain Coinvestors AngelList Syndicate, Greycroft, iNovia Capital, NextView Ventures, Trajectory Ventures, True Ventures.
EnsoData has raised $51.0M across 4 funding rounds. Most recently, it raised $20.0M Series B in June 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2025 | $20.0M Series B | Ulu Ventures, Zetta Venture Partners | |
| Apr 1, 2022 | $20.0M Series A | Baird Capital, Colle Capital, gener8tor, Zetta Venture Partners | |
| Jun 1, 2020 | $9.0M Series A | Baird Capital, Colle Capital, gener8tor, Ulu Ventures, Zetta Venture Partners | |
| Mar 1, 2018 | $2.0M Seed | Blockchain Coinvestors AngelList Syndicate, Colle Capital, Greycroft, iNovia Capital, NextView Ventures, Trajectory Ventures, True Ventures |
